This in our opinion, combined with the effect of GR127934 (Fig. 10) suggest that part of the anti-migraine effect of Lasmiditan is inhibition of CGRP release through “unspecific” activation of 5-HT1B and 5-HT1D receptors in the TG. The gene discussed is HTR1B; the disease is migraine disorder.